CLYM · Climb Bio Inc
United States · RS rating 53 · As of 2026-10-14
| Price | 10.29 USD |
|---|---|
| 1-day change | -0.2% |
| RS rating (overall / 1M / 3M / 12M) | 53 / 8 / 21 / 98 |
| Stage | Advancing |
| Composite / Minervini / CANSLIM score | 31 / 49 / 16 |
| Industry group (rank) | Medical-Biomed/Biotech (167) |
| EPS growth Q/Q | -36.8% |
| Sales growth Q/Q | – |
| Distance from 52-week high | +42.3% |
| Market cap (USD) | $430.9M |